P-22: Efficacy and safety of perindopril erbumine, an angiotensin converting enzyme inhibitor (ACE-I), in 2269 elderly hypertensive patients: subgroup analysis of a 12-week, open-label, Aceon® Community Trial (ACT)

There is little data on the management of elderly hypertensive patients in family practice. Furthermore, it has been well demonstrated that treatment of these patients decreases their risk of cardiovascular disease. The efficacy and safety of perindopril erbumine were analyzed in a subgroup of elderly (≥65 years) hypertensive patients (n=2269) who were included in a large, 12-Week, open-label, community study. All patients were treated with perindopril 4 mg QD for 6 weeks and could be uptitrated by the investigator to perindopril 8 mg QD for an additional 6 weeks depending on blood pressure (BP) response. Seated BPs were measured at Baseline (antihypertensives withdrawn), Week 6, and Week 12. Following 12 Weeks of treatment, perindopril resulted in a significant reduction in systolic (SBP) (-18.2±0.5 mmHg, p